{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:35:56Z","timestamp":1785180956625,"version":"3.55.0"},"posted":{"date-parts":[[2021,2,5]]},"group-title":"Pharmacology and Toxicology","reference-count":29,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Favipiravir (FAV; T-705) has been approved for use as an anti-influenza therapeutic and has reports against a wide range of viruses (e.g., Ebola virus, rabies and norovirus). Most recently FAV has been reported to demonstrate activity against SARS-CoV-2. Repurposing opportunities have been intensively studied with only limited success to date. If successful, repurposing will allow interventions to become more rapidly available than development of new chemical entities. Pre-clinical and clinical investigations of FAV require robust, reproducible and sensitive bioanalytical assay. Here, a liquid chromatography tandem mass spectrometry assay is presented which was linear from 0.78-200 ng\/mL Accuracy and precision ranged between 89% and 110%, 101% and 106%, respectively. The presented assay here has applications in both pre-clinical and clinical research and may be used to facilitate further investigations into the application of FAV against SARS-CoV-2.<\/jats:p>","DOI":"10.1101\/2021.02.03.429628","type":"posted-content","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T18:11:32Z","timestamp":1612548692000},"source":"Crossref","is-referenced-by-count":4,"title":["Development of a highly sensitive bioanalytical assay for the quantification of favipiravir"],"prefix":"10.64898","author":[{"given":"Paul","family":"Curley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Neary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-1885","authenticated-orcid":false,"given":"Usman","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Pertinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Box","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajith KR","family":"Rajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Valentijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve P","family":"Rannard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024080513053596000_2021.02.03.429628v1.1","doi-asserted-by":"crossref","unstructured":"Shiraki, K. and T. Daikoku , Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics, 2020: p. 107512.","DOI":"10.1016\/j.pharmthera.2020.107512"},{"key":"2024080513053596000_2021.02.03.429628v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.03.003"},{"issue":"10","key":"2024080513053596000_2021.02.03.429628v1.3","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1021\/acs.jmedchem.5b01933","article-title":"Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-nucleosides as favipiravir (T-705) analogues","volume":"59","year":"2016","journal-title":"Journal of medicinal chemistry"},{"key":"2024080513053596000_2021.02.03.429628v1.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909603107"},{"key":"2024080513053596000_2021.02.03.429628v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"2024080513053596000_2021.02.03.429628v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"2024080513053596000_2021.02.03.429628v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"2024080513053596000_2021.02.03.429628v1.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002804"},{"key":"2024080513053596000_2021.02.03.429628v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv522"},{"key":"2024080513053596000_2021.02.03.429628v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.12.006"},{"key":"2024080513053596000_2021.02.03.429628v1.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014441117"},{"key":"2024080513053596000_2021.02.03.429628v1.12","doi-asserted-by":"crossref","unstructured":"Arshad, U. , et al., Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. medRxiv, 2020.","DOI":"10.1101\/2020.04.16.20068379"},{"key":"2024080513053596000_2021.02.03.429628v1.13","doi-asserted-by":"crossref","first-page":"103204","DOI":"10.1016\/j.ebiom.2020.103204","article-title":"Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19","volume":"63","year":"2021","journal-title":"EBioMedicine"},{"key":"2024080513053596000_2021.02.03.429628v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"2024080513053596000_2021.02.03.429628v1.15","doi-asserted-by":"crossref","unstructured":"Pertinez, H. , et al., Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5\u2019-triphosphate exposure to support posology for SARS-CoV-2. medRxiv, 2021.","DOI":"10.1101\/2021.01.03.21249159"},{"key":"2024080513053596000_2021.02.03.429628v1.16","unstructured":"medicine, U.S.N.I.o.H.N.l.o. clinicaltrials.gov search for favipiravir clinical trials against COVID19. 2020; Available from: https:\/\/clinicaltrials.gov\/search\/intervention=Favipiravir."},{"key":"2024080513053596000_2021.02.03.429628v1.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389"},{"key":"2024080513053596000_2021.02.03.429628v1.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002614"},{"key":"2024080513053596000_2021.02.03.429628v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp274"},{"key":"2024080513053596000_2021.02.03.429628v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.12.021"},{"key":"2024080513053596000_2021.02.03.429628v1.21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.chemosphere.2016.11.102","article-title":"Fate of new three anti-influenza drugs and one prodrug in the water environment","volume":"169","year":"2017","journal-title":"Chemosphere"},{"key":"2024080513053596000_2021.02.03.429628v1.22","doi-asserted-by":"crossref","unstructured":"Pires de Mello, C.P. , et al., Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrob Agents Chemother, 2018. 62(9).","DOI":"10.1128\/AAC.00967-18"},{"key":"2024080513053596000_2021.02.03.429628v1.23","unstructured":"Administration, U.S.D.o.H.a.H.S.F.a.D., Bioanalytical Method Validation Guidance for Industry, U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a.R.C.C.f.V.M. (CVM), Editor. 2018. p. 44."},{"issue":"1","key":"2024080513053596000_2021.02.03.429628v1.24","first-page":"54","article-title":"Strategies for the Detection and Elimination of Matrix Effects in Quantitative LC-MS Analysis","volume":"32","year":"2014","journal-title":"Lc Gc North America"},{"key":"2024080513053596000_2021.02.03.429628v1.25","unstructured":"(FDA), U.S.F.D.A., Bioanalytical Method Validation Guidance for Industry, C.f.D.E.a. Research and C.f.V. Medicine, Editors. 2020."},{"key":"2024080513053596000_2021.02.03.429628v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku420"},{"issue":"6","key":"2024080513053596000_2021.02.03.429628v1.27","doi-asserted-by":"crossref","first-page":"e63305","DOI":"10.1371\/journal.pone.0063305","article-title":"A sensitive and selective liquid chromatography\/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma","volume":"8","year":"2013","journal-title":"PLoS One"},{"issue":"23","key":"2024080513053596000_2021.02.03.429628v1.28","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4155\/bio-2017-0214","article-title":"Matrix effects and application of matrix effect factor","volume":"9","year":"2017","journal-title":"Bioanalysis"},{"key":"2024080513053596000_2021.02.03.429628v1.29","doi-asserted-by":"publisher","DOI":"10.1039\/C4MD00148F"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.02.03.429628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:19:02Z","timestamp":1768439942000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2021.02.03.429628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1101\/2021.02.03.429628","relation":{},"subject":[],"published":{"date-parts":[[2021,2,5]]},"subtype":"preprint"}}